Leading brokerage firm Emkay Research has maintained a bullish stance on Sun Pharma, assigning a ‘BUY’ rating with a price ...

Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...

ICICI Securities is bullish on Sun Pharmaceutical Industries recommended buy rating on the stock with a target price of Rs 1895 in its research report dated March 11, 2025.

What was Sun Pharmaceuticals Industries Ltd share price previously? Sun Pharmaceuticals Industries Ltd share price was up by 1.03% from the previous closing price of ₹1,732.35. Who are peers of ...

Sun Pharma share price today reached ₹1,651.80, a 2.50% rise from its last close of ₹1,611.50. The rise is despite the ...

While the brokerage remains positive on the growth outlook for Sun’s key specialty brands ... Additionally, the brokerage lowered its target PE multiple to 35x (from 40x) to account for macro ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Sun Pharma will pay an upfront cash payment of $4.1 per share, which amounts to an aggregate consideration of $355 million.

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company ...